SUYI PARK: Open Payments
NPI 1932177904 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$267 in 12 payments from 8 companies in 2025. Trend: 2023 $1,326 · 2024 $836 · 2025 $267
Food & beverage: $267
| Company | Payments | Amount |
|---|---|---|
| Indivior Inc. | 3 | $78 |
| Dexcom, Inc. | 2 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| Gilead Sciences, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Novo Nordisk Inc | 1 | $15 |
Products named: SUBLOCADE, Dexcom G6 Transmitter, FARXIGA, AMYVID, RECORLEV, Veozah, BREZTRI, Rybelsus.
Industry payments across MD — which companies pay providers there.
